Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV): 3 pipeline candidates · 1 upcoming catalyst. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
N/A
D/E 0.09 · 0% dilution
Lead: Phase 2/Phase 3
3 candidates
1 upcoming, next in ~4896d
0 buys · 34 sells (180d)
A transparent, data-derived signal for Roivant Sciences Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$21.6B
Cash
$1.4B
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| brepocitinib | — |
| imvt-1402 | Phase 2/Phase 3 |
| mosliciguat | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
438
Total value held
$14.09B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 77,981,253 | $2.16B |
| morgan stanley | 51,828,325 | $1.44B |
| blackrock, inc. | 44,254,260 | $1.23B |
| vanguard capital management llc | 41,361,144 | $1.15B |
| vanguard portfolio management llc | 19,838,698 | $549.5M |
| perceptive advisors llc | 16,570,922 | $459.0M |
| state street corp | 16,186,613 | $448.4M |
| adage capital partners gp, l.l.c. | 12,794,097 | $354.4M |
| goldman sachs group inc | 11,111,591 | $307.8M |
| geode capital management, llc | 10,182,477 | $282.1M |
Showing top 10 of 438 institutional holders of Roivant Sciences Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Roivant Sciences Ltd.'s pipeline?
Roivant Sciences Ltd. (ROIV) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Roivant Sciences Ltd.'s next catalyst?
Roivant Sciences Ltd.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VTAMA" — expected November 13, 2039.
What is Roivant Sciences Ltd.'s market capitalization?
Roivant Sciences Ltd.'s market capitalization is approximately $21.6B.
Who is the CEO of Roivant Sciences Ltd.?
Mr. Matthew Gline is the chief executive officer of Roivant Sciences Ltd. (ROIV).
Get the full picture on Roivant Sciences Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.